The 7 major Fanconi anemia markets reached a value of US$ 49.2 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 78.8 Million by 2034, exhibiting a growth rate (CAGR) of 4.38% during 2024-2034.
Report Attribute
|
Key Statistics
|
---|---|
Base Year |
2023
|
Forecast Years | 2024-2034 |
Historical Years |
2018-2023
|
Market Size in 2023
|
US$ 49.2 Million |
Market Forecast in 2034
|
US$ 78.8 Million |
Market Growth Rate (2024-2034)
|
4.38% |
The Fanconi anemia market has been comprehensively analyzed in IMARC's new report titled "Fanconi Anemia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Fanconi anemia is a rare genetic disorder characterized by bone marrow failure, increased susceptibility to cancer, and various physical abnormalities. In this condition, the bone marrow, which is responsible for producing new blood cells, fails to generate enough red blood cells, white blood cells, and platelets. As a result, individuals suffering from the ailment may experience fatigue, headaches, difficulty breathing, increased infections, and a higher risk of bleeding. Various other common indications associated with the disease include physical abnormalities, such as skeletal deformities, malformations of the thumbs or upper limbs, heart defects, balance problems, skin pigmentation changes, unusual spinal curves, hearing loss, etc. The diagnosis of Fanconi anemia is typically made through a combination of clinical assessment, physical examination, and biopsy. The healthcare professionals usually suggest several blood workups, including hemoglobin electrophoresis, complete blood count, peripheral smear test, etc., to evaluate the type, appearance, and function of blood cells. They may also conduct biopsy of the bone marrow to look for characteristic changes in the tissues and cells among patients.
The rising cases of genetic disorders causing defective DNA repair and chromosomal instability are primarily driving the Fanconi anemia market. Additionally, the escalating usage of androgen therapy, which involves the administration of testosterone to stimulate the production of red blood cells within the body, is also propelling the market growth. In line with this, the widespread adoption of steroidal drugs that help to improve energy levels and physical strength in patients with Fanconi anemia is creating a positive outlook for the market. Furthermore, the increasing application of stem cell transplants for treating severe disease conditions that do not respond to other pharmacological therapies is also augmenting the market growth. This procedure involves the replacement of the diseased bone marrow with healthy stem cells in order to restore a normal blood cell count. Besides this, the emerging popularity of preimplantation genetic testing, which is used for assisted reproduction and to determine chromosomal defects in embryos formed through in-vitro fertilization, thereby preventing transmission of gene abnormalities, is expected to drive the Fanconi anemia during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the Fanconi anemia market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for Fanconi anemia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Fanconi anemia market in any manner.
RP-L102 is Rocket's lentiviral vector-based gene therapy in development for individuals with Fanconi anemia. It contains autologous (patient-derived) hematopoietic stem cells that have been genetically engineered with a lentiviral vector to include a functional copy of the FANCA gene.
Time Period of the Study
Countries Covered
Analysis Covered Across Each Country
This report also provides a detailed analysis of the current Fanconi anemia marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Late-Stage Pipeline Drugs
Drugs | Company Name |
---|---|
RP-L102 | Rocket Pharmaceuticals |
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Market Insights
Epidemiology Insights
Fanconi Anemia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies